Rela-flox Mouse
一般名
Rela-flox
製品ID
S-CKO-04767
背景情報
C57BL/6JCya
系統ID
CKOCMP-19697-Rela-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Rela-flox Mouse(カタログ番号S-CKO-04767)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Rela-flox
系統ID
CKOCMP-19697-Rela-B6J-VA
遺伝子名
製品ID
S-CKO-04767
遺伝子別名
p65, p65 NFkB, p65 NF-kappa B
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 19
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000025867
NCBIトランスクリプトID
NM_009045
ターゲット領域
Exon 5~6
有効領域の大きさ
~1.1 kb
遺伝子研究の概要
RELA, also known as NF-κB p65, is a subunit of nuclear factor kappa B (NF-κB), a transcription factor involved in various biological processes, including immune response, inflammation, cell survival, and proliferation. The NF-κB pathway is a key signaling cascade that plays a crucial role in regulating the expression of genes involved in these processes [3,5,7,8,9].
In silica-induced pulmonary fibrosis, RELA-mediated upregulation of LINC03047 promotes ferroptosis and epithelial-mesenchymal transition (EMT) via SLC39A14, suggesting its role in the progression of silicosis [1]. In supratentorial ependymoma, the C11orf95-RELA fusion protein modulates chromatin states and mediates chromatin interactions, leading to transcriptional reprogramming [2]. In hypopharyngeal cancer, RELA is required for CD271 expression and stem-like characteristics [3]. In human T cells, RELA tunes innate-like interferon I/III responses [4]. In oral squamous cell carcinoma, RELA promotes tumor progression via the TFAP2A-Wnt/β-catenin signaling pathway [5]. In cancer cells, mitochondrial RelA promotes mtDNA G-quadruplex formation for hypoxia adaptation [6]. WSB1/2 target chromatin-bound lysine-methylated RelA for proteasomal degradation and NF-κB termination [7]. In pancreatic cancer, NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis [8]. The C11orf95-RELA fusion drives aberrant gene expression through unique epigenetic regulation for ependymoma formation [9].
In conclusion, RELA is a crucial component of the NF-κB pathway, playing important roles in multiple biological processes and disease conditions such as fibrosis, various cancers, and immune-related responses. Studies using different models, though not specifically KO/CKO mouse models in the provided references, have revealed its diverse functions in these contexts, contributing to our understanding of disease mechanisms and potential therapeutic targets.
References:
1. Zhang, Binbin, Wang, Enze, Zhou, Sijing, Cao, Chao, Wang, Ran. 2024. RELA-mediated upregulation of LINC03047 promotes ferroptosis in silica-induced pulmonary fibrosis via SLC39A14. In Free radical biology & medicine, 223, 250-262. doi:10.1016/j.freeradbiomed.2024.08.002. https://pubmed.ncbi.nlm.nih.gov/39111583/
2. Zhu, Jacqueline Jufen, Jillette, Nathaniel, Li, Xiao-Nan, Cheng, Albert Wu, Lau, Ching C. 2020. C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma. In Acta neuropathologica, 140, 951-960. doi:10.1007/s00401-020-02225-8. https://pubmed.ncbi.nlm.nih.gov/32909151/
3. Nakazato, Akira, Mochizuki, Mai, Shibuya-Takahashi, Rie, Asada, Yukinori, Tamai, Keiichi. 2022. RELA is required for CD271 expression and stem-like characteristics in hypopharyngeal cancer. In Scientific reports, 12, 17751. doi:10.1038/s41598-022-22736-6. https://pubmed.ncbi.nlm.nih.gov/36273237/
4. Jeremiah, Nadia, Ferran, Hermine, Antoniadou, Konstantina, Benaroch, Philippe, Manel, Nicolas. 2023. RELA tunes innate-like interferon I/III responses in human T cells. In The Journal of experimental medicine, 220, . doi:10.1084/jem.20220666. https://pubmed.ncbi.nlm.nih.gov/36820829/
5. Yang, Kaicheng, Zhao, Jianguang, Liu, Shenghui, Man, Shasha. 2023. RELA promotes the progression of oral squamous cell carcinoma via TFAP2A-Wnt/β-catenin signaling. In Molecular carcinogenesis, 62, 641-651. doi:10.1002/mc.23512. https://pubmed.ncbi.nlm.nih.gov/36789977/
6. Tang, Gui-Xue, Li, Mao-Lin, Zhou, Cui, Chen, Xiu-Cai, Tan, Jia-Heng. 2024. Mitochondrial RelA empowers mtDNA G-quadruplex formation for hypoxia adaptation in cancer cells. In Cell chemical biology, 31, 1800-1814.e7. doi:10.1016/j.chembiol.2024.05.003. https://pubmed.ncbi.nlm.nih.gov/38821064/
7. Zhang, Jie, Yu, Yuanyuan, Zou, Xiuqun, Chen, Lin-Feng, Yang, Xiao-Dong. . WSB1/2 target chromatin-bound lysine-methylated RelA for proteasomal degradation and NF-κB termination. In Nucleic acids research, 52, 4969-4984. doi:10.1093/nar/gkae161. https://pubmed.ncbi.nlm.nih.gov/38452206/
8. Geismann, Claudia, Hauser, Charlotte, Grohmann, Frauke, Schreiber, Stefan, Arlt, Alexander. 2023. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. In Cell death & disease, 14, 3. doi:10.1038/s41419-022-05535-9. https://pubmed.ncbi.nlm.nih.gov/36596765/
9. Ozawa, Tatsuya, Kaneko, Syuzo, Szulzewsky, Frank, Hamamoto, Ryuji, Ichimura, Koichi. 2021. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. In Acta neuropathologica communications, 9, 36. doi:10.1186/s40478-021-01135-4. https://pubmed.ncbi.nlm.nih.gov/33685520/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
